BluMaiden Biosciences – Revolutionizing Drug Discovery

Published by Biotech Connection Singapore on

By Qian Yi Lee

 

BluMaiden Biosciences, a Singapore-headquartered biotechnology company, focuses on advancing small molecule drug discovery by looking within the human body through its flagship platform, MAIDENTM, which combines computational biology with computational chemistry approaches to discover the next blockbuster drug. I spoke to BluMaiden’s founder and CEO, Damien Keogh, to find out more about his experience starting and growing a biotech start-up in Singapore and seek his advice for aspiring start-ups in Singapore.

 

Dr Damien Keogh, Founder and CEO

 

QY: What is the story behind BluMaiden? How did it get founded?

DK: I have always been fascinated with metabolite biology, a theme that has run throughout my research career, which has now spanned academia, venture capital, and biotech. I’ve known our scientific co-founder, Rohan Williams, since I moved to work at the Singapore Centre for Environmental Life Sciences Engineering (SCELSE) more than 11 years ago. Rohan is a specialist in computational biology, particularly in bioinformatics and systems biology, and he is a principal investigator at SCELSE NUS and SMART. Together, we conceptualized the science and technological approach BluMaiden has developed. Additionally, Robert Meyer, another long-time friend, joined as co-founder. Robert, on the other hand, is an extremely experienced serial entrepreneur and investor with multiple successful companies under his belt. Prior to launching an investment firm, he co-founded SGX-listed Halcyon Agri Corporation having served as its CEO for seven years. Together, the three of us collaborated to develop a comprehensive business plan, and we invested the initial capital to launch the business back in 2020. With BluMaiden Biosciences, our aim was to create a sustainable business with biotech moonshot opportunities, ultimately tackling major challenges that Pharma cannot currently overcome, thereby creating new medicines for patients in need.

 

QY: Could you share more about BluMaiden’s technology and its applications? How does BluMaiden differentiate itself from its competitors in the field of AI-based drug discovery?

DK: Unlike traditional biotech companies, which initially focus mainly on wet lab biological research, TechBio better describes BluMaiden’s approach, where advanced computational tools and AI are leveraged to accelerate early-stage breakthroughs. While we further develop these assets in the wet lab, our approach offers a significant initial advantage by harnessing this technology to expedite discovery. Although there are many exceptional companies driving innovation in computationally driven small molecule drug discovery, such as Schrodinger and Insilico Medicine, we believe our approach stands out. Our emphasis on combining computational analysis with human clinical evidence provides crucial physiological relevance in our drug discovery efforts. While we’re still in the early stages compared to established leaders like Schrodinger and Insilico Medicine, we believe that our starting point and focus on human-evidence reference offers a significant advantage as we forge our path forward. We employ highly customized machine learning models and feature engineering to capture the health-predictive signals in microbiome and clinical data. Additionally, we leverage long-range semantic relationships in large-scale heterogenous datasets to predict new curative opportunities. Additionally, integrating this approach with our Pharma Service has already proven beneficial, enhancing the quality and standardization of our offerings while bringing us closer to valuable Pharma scientific expertise, and providing access to high-quality data to accelerate our drug discovery programs.

 

QY: Can you share more about the business model of your company? How do you market your products? What role does partnership and collaboration play in building your portfolio?

DK:  We have already commercialized our products and services, with a strong focus on key markets in the USA and Europe. With a robust pipeline of Pharma engagements and expanding sales channels, our goal is to build sustainability by generating early revenue and accelerating development. Strategic partnerships with major Tech and Life Science firms are fundamental to our operation, enabling us to deploy our technologies and collaborate not only in Singapore but also internationally in the USA and Europe.

 

QY: Congratulations on closing your latest round of funding. Can you tell us more about the challenges you have faced fundraising in the current economic environment and how you managed to overcome them?

DK: Thank you. There’s no one-size-fits-all solution to the current challenges of fundraising within the Biotech sector. Every founder is doing their best for their company, and additionally, there’s no single “type” of company. Aligning with investors requires conversation, negotiation, and a lot of work and evaluation on both sides. The most important factor is doing what’s best for the company’s growth. The goal is to find like-minded individuals and funds that see the bigger picture and calculate the risk-return opportunity. We are very fortunate to have early shareholders who have supported us since the beginning. As a venture creation company, not a university spin-out, this support is crucial to our ecosystem in Singapore. Our latest round, with Elev8VC and SEEDS Capital, is a tremendous validation of our efforts.

 

QY: What are your thoughts about the funding ecosystem for aspiring start-ups in Singapore?

DK: Previously, I worked in Venture Capital at a time when there were really only three funds investing in Singapore’s biotechnology companies. The Singapore biotech ecosystem has made tremendous progress since then, but both the funding environment and company landscape are still maturing. This presents opportunities for growth, which is encouraging. Independent venture creation represents a significant opportunity for accelerating the ecosystem and driving innovation towards a commercial path; however, funding this pathway remains a major challenge.

For innovators within the academic sector, my advice is to maximize your time at the university, leveraging grants and accelerators before spinning out. Advance your products as much as possible through these resources before spinning off. Ensure that your solution addresses a clearly defined market need and build a robust business model.

 

QY: What was the largest challenge you faced with BluMaiden?

DK: There are many challenges when starting a biotechnology company. Recruitment has consistently required significant time and energy. Establishing a company post-Covid was particularly challenging, especially in finding domain experts in the fields we needed. Fortunately, our first two employees, Zhao Peng and Artur Matysik, were incredibly talented scientists I had previously work with in academia and venture capital. They set high standards within the team.

Initially, we worked with several remote specialists, but we eventually consolidated our operations in Singapore. Our team now boasts expertise across multiple domains of science and technology. Our greatest asset is effective communication and understanding across disciplines. Oleg Moskvin, our Head of Computational Science, is one of the most talented and creative people I’ve worked with.

We invest substantial efforts in recruiting the right people, and this team has become a magnet for our current recruitment efforts. Feedback from new employees consistently highlights that the intellectual calibre of the team as a primary attraction during the recruitment process.

 

BluMaiden Team: Damien, Oleg and Peng

 

QY: With these challenges with hiring and funding, why did you decide to set up BluMaiden in Singapore?

DK: I have lived in Singapore for a long time now; my family is here, and all of BluMaiden’s founders are located here. We’re not moving either. I don’t think BluMaiden would have existed if I were not in Singapore. Singapore boasts an exceptionally diverse community of individuals from various backgrounds, creating a rich environment to network and seek opportunity. One notable advantage of our first year was the relative ease of connecting with key individuals in Singapore who, due to post-Covid travel limitations, were grounded and less engaged in frequent international travel. This facilitated the formation an exception board of directors, advisory board, and scientific team, which might have been more challenging under normal circumstances. For example, Michael Tillmann, who joined the company as Chairman of the Board of Directors a year into our growth, is also considered a founding member. His contributions have been pivotal to our development and strategic positioning. Michael is a seasoned CEO, having served Roche Diagnostics as Asia Pacific and North America CEO with a seat at the Roche Global Executive Board.

 

QY: What are your plans for the future of BluMaiden? Where do you see it in 5-10 years?

DK: While 5-10 years is a long way off, I’m confident that our company’s supporters will be impressed by our significant growth and returns. Above all, our focus will remain on positively impacting patients’ lives through our products and services. Personally, I aspire to be in a position where I have the time to support others on their entrepreneurial journeys.

 

QY: What other advice would you give to aspiring founders in the biotech sector?

DK: Don’t be afraid to take a risk and try. In a new business venture where there may be uncertainty in both technology and market, you have take calculated risk, and capture the opportunity. Seek advice from experts with prior success, evaluate the risk-reward and work with full dedication towards that goal.

Biotech Connection Singapore (BCS) is part of an international network of non-profit organizations, that aims to promote the transfer of ideas from theory to real world applications by providing a platform for fostering interaction between academia, industry and businesses.